IRIS
BOCCARDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 40.220
AS - Asia 4.075
NA - Nord America 3.589
Continente sconosciuto - Info sul continente non disponibili 712
SA - Sud America 367
AF - Africa 82
OC - Oceania 1
Totale 49.046
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 39.485
US - Stati Uniti d'America 3.305
SG - Singapore 1.732
CN - Cina 1.074
VN - Vietnam 548
FR - Francia 328
BD - Bangladesh 327
BR - Brasile 221
HK - Hong Kong 130
FI - Finlandia 114
CA - Canada 92
DE - Germania 76
AR - Argentina 56
JP - Giappone 55
GB - Regno Unito 53
MX - Messico 53
JM - Giamaica 33
IN - India 29
CR - Costa Rica 28
ES - Italia 24
ID - Indonesia 24
CH - Svizzera 23
IQ - Iraq 22
VE - Venezuela 22
CO - Colombia 20
EC - Ecuador 20
NL - Olanda 19
HN - Honduras 17
PH - Filippine 15
SC - Seychelles 15
RU - Federazione Russa 14
GT - Guatemala 13
PL - Polonia 13
SA - Arabia Saudita 13
IE - Irlanda 12
ZA - Sudafrica 11
MA - Marocco 10
NI - Nicaragua 10
PK - Pakistan 10
TT - Trinidad e Tobago 10
UA - Ucraina 10
MY - Malesia 9
PE - Perù 9
SE - Svezia 9
TH - Thailandia 9
TR - Turchia 9
CL - Cile 8
DZ - Algeria 8
JO - Giordania 8
SV - El Salvador 8
AZ - Azerbaigian 6
KE - Kenya 6
PR - Porto Rico 6
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
NP - Nepal 5
AL - Albania 4
BH - Bahrain 4
DO - Repubblica Dominicana 4
KZ - Kazakistan 4
LB - Libano 4
LT - Lituania 4
RO - Romania 4
RS - Serbia 4
SN - Senegal 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
UZ - Uzbekistan 4
BB - Barbados 3
DK - Danimarca 3
ET - Etiopia 3
IR - Iran 3
KR - Corea 3
SI - Slovenia 3
TN - Tunisia 3
AF - Afghanistan, Repubblica islamica di 2
AT - Austria 2
BE - Belgio 2
BS - Bahamas 2
BW - Botswana 2
CI - Costa d'Avorio 2
EG - Egitto 2
GA - Gabon 2
HU - Ungheria 2
KW - Kuwait 2
LV - Lettonia 2
MM - Myanmar 2
MU - Mauritius 2
NO - Norvegia 2
OM - Oman 2
PS - Palestinian Territory 2
QA - Qatar 2
RE - Reunion 2
SX - ???statistics.table.value.countryCode.SX??? 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BG - Bulgaria 1
BM - Bermuda 1
Totale 48.311
Salva come PNG Salva come JPEG
Città #
Genova 25.260
Genoa 8.193
Rapallo 3.374
Vado Ligure 2.245
San Jose 903
Singapore 829
Ashburn 330
Lauterbourg 317
Ho Chi Minh City 167
New York 148
Beijing 141
Hanoi 127
Hong Kong 116
Helsinki 114
Santa Clara 106
Bordighera 65
Los Angeles 64
Milan 57
Frankfurt am Main 56
Chicago 54
Tokyo 46
Council Bluffs 43
Rome 40
Phoenix 38
Dallas 35
Buffalo 29
Tianjin 27
Mexico City 26
Philadelphia 24
São Paulo 24
San José 23
Naples 21
Houston 20
Zurich 20
Haiphong 19
Atlanta 17
Kingston 17
Las Vegas 17
Orem 17
Charlotte 16
Guangzhou 16
Orlando 16
Montreal 15
Toronto 14
City of London 13
Newark 13
Queens 13
San Francisco 13
Seattle 13
Biên Hòa 12
Boardman 12
Da Nang 12
Miami 12
Boston 11
Guatemala City 11
Washington 11
Brooklyn 10
Cleveland 10
Dublin 10
Hải Dương 10
Louisville 10
Rio de Janeiro 10
Amsterdam 9
Detroit 9
London 9
Managua 9
Cardiff 8
Jakarta 8
San Salvador 8
Shanghai 8
Stockholm 8
The Bronx 8
Warsaw 8
Amman 7
Bangkok 7
Brasília 7
Curitiba 7
El Paso 7
Guayaquil 7
Madrid 7
Palermo 7
Porto Alegre 7
Turin 7
Winnipeg 7
Arroyo Grande 6
Bologna 6
Bắc Ninh 6
Can Tho 6
Chennai 6
Chula Vista 6
Garland 6
Minneapolis 6
Mumbai 6
New Orleans 6
Portland 6
San Antonio 6
Shenzhen 6
Vĩnh Long 6
Wilmington 6
Baghdad 5
Totale 43.716
Salva come PNG Salva come JPEG
Nome #
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 321
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 262
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: Meta-analysis of individual patient data from ten randomised trials 237
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer 236
A Case of Advanced Mucinous Adenocarcinoma of Bladder in an Adult Patient Treated With Capecitabine-Based Chemotherapy and Review of Literature 221
Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. 221
Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer 219
Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials 215
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer 211
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 211
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma 211
A Case of Plasmacytoid Variant of Bladder Cancer with a Single Penile Metastasis and a Complete Response to Carboplatin-Based Chemotherapy and Review of the Literature 210
Androgen-deprivation therapy is more than palliation in oligometastatic prostate cancer 207
Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy 205
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. 205
Apalutamide treatment and metastasis-free survival in prostate cancer 201
A hnRNP K–AR-related signature reflects progression toward castration-resistant prostate cancer 200
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials 200
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial 200
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 199
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes 198
Management of young women with early breast cancer 194
Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report 192
Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study 192
Efficacy of motesanib diphosphate in non-small-cell lung cancer. 190
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials 188
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 188
Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery 187
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. 186
Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa) 186
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. 184
Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. 183
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 183
Differential expression of nuclear lamins in normal and cancerous prostate tissues 182
Effects of three cytokine regimens on hematologic recovery and progenitor cell mobilization after high-dose cyclophosphamide, etoposide, and cisplatin. 182
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 182
Belagenpumatucel-L for the treatment of non-small cell lung cancer 180
Targeting androgen-independent pathways: new chances for patients with prostate cancer? 180
Adjuvant chemotherapy of bladder cancer. 178
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study 177
Next Generation Sequencing In Non-Small Cell Lung Cancer: New Avenues Toward The Personalized Medicine. 177
Prognostic value of nuclear matrix protein expression in localized prostate cancer. 177
Immunotherapy for genitourinary cancer: State of the art and new perspectives 176
Genitourinary tumours in the targeted therapies era: New advances in clinical practice and future perspectives 176
Paclitaxel plus organoplatins: still the gold standard in advanced ovarian cancer? 175
The prognostic role of baseline metabolic tumor burden and systemic inflammation biomarkers in metastatic castration-resistant prostate cancer patients treated with Radium-223: A proof of concept study 175
Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results 174
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials 174
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study 173
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials 173
Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. 172
May adjuvant therapy play a role for the management of renal cell carcinoma? A review of literature and ongoing trials 172
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial 172
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients 171
Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer 170
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. 170
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 170
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 170
A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group. 169
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question! 168
Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death 166
68P * Prognostic value of periostin (PN) expression in early breast cancer (BCa): Long-term mortality outcomes 166
Alternating chemo-radiotherapy in bladder cancer: a conservative approach. 165
D-TRP-6-LH-RH treatment of advanced prostatic cancer 165
Combinations of hormonal therapy and chemotherapy 165
Bone metastases from prostate cancer: hormonal therapy 165
Adjuvant therapy for patients with node negative breast cancer. 164
Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast 164
Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis 164
Urethral stricture and scrotal abscess: a rare case presentation of penile cancer and review of the literature 164
Ovarian ablation in early breast cancer: overview of the randomised trials. 163
Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. 163
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. 162
Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. 160
Cardiovascular disease (CVD) markers in patients(pts) with prostate cancer(PCa) treated with GN-RH agonists(AG) or antagonist(AN): a prospective cohort study 160
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. 159
Leiomyosarcoma of the broad ligament: a case report and review of literature. 158
Periostin: A Novel Prognostic and Therapeutic Target For Genitourinary Cancer? 158
Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. 157
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study 157
Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. 157
Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era 156
Communicating cancer diagnosis and prognosis: when the target is the elderly patient-a GIOGer study. 156
A large SEER- based study of survival trends in patients with de novo metastatic prostate cancer 156
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. 155
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 155
Use of metronomic chemotherapy in oncology: results from a national Italian survey. 154
Nafarelin acetate and benign prostatic hyperplasia. 153
Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer. 153
Priming action on progesterone receptor synthesis by estradiol and tamoxifen in the 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinoma. 153
Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl) in prostate cancer. An Italian multicentric trial. 153
Prognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma. 153
Effects of high-dose medroxyprogesterone acetate on blood-clotting and platelet function. 153
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer 153
Switching to aromatase inhibitors in early breast cancer. 153
Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study 153
Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study 152
Presence and distribution of growth factors in breast cyst fluid. 151
Carboplatin in advanced hormone refractory prostatic cancer patients. 151
Ifosfamide in urologic cancer. 151
Totale 17.874
Salva come PNG Salva come JPEG
Categoria #
all - tutte 156.102
article - articoli 140.241
book - libri 732
conference - conferenze 317
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 14.812
Totale 312.204
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.820 0 0 202 604 152 290 132 1.154 233 379 96 578
2022/20234.052 409 225 46 383 741 831 7 272 729 30 317 62
2023/20241.832 85 294 46 205 154 317 99 113 84 61 94 280
2024/20255.476 130 458 218 402 719 539 482 884 223 262 470 689
2025/20269.687 1.031 311 661 742 1.274 1.067 1.641 429 603 911 599 418
2026/20272.060 1.055 309 696 0 0 0 0 0 0 0 0 0
Totale 49.046